Healthcare Industry News: diabetes
News Release - April 19, 2016
Rodney D. Altman, MD Joins Valeritas Board of DirectorsValeritas Expands Its Board of Directors
BRIDGEWATER, New Jersey, April 19, 2016 -- (Healthcare Sales & Marketing Network) -- Valeritas, Inc. announced today that Rodney D. Altman, MD has been elected to the company's board as an independent director. Dr. Altman brings a thorough understanding of the healthcare system with 16 years of venture capital, healthcare administrative and operations, as well as over 25 years of extensive clinical experience. He recently joined Spindletop Capital as a Managing Director. Dr. Altman also currently serves as board director at Siris Medical, and as an advisor to BDC Ventures and to several healthcare start-ups. Prior to joining Spindeltop, he had an operating role at Team Health (TMH), a healthcare provider outsourcing company.
Before Team Health, he served as a Senior Partner at CMEA Capital where he invested in SurgiQuest (acquired by Conmed), Visiogen (acquired by Abbott), InSound Medical (acquired by Sonova), and VasoNova (acquired by Teleflex). He was Chairman of the Board of VasoNova.
"Dr. Altman is a highly respected physician and a proven venture capitalist. His clinical knowledge, business acumen and prior board roles bring a breadth of valuable experiences to the Valeritas Board. We are delighted to welcome Dr. Altman to the Valeritas Board, with full confidence that his contribution to our advancing company will be profound," said John Timberlake, president and CEO at Valeritas.
Dr. Altman's other roles have included Co-Founder and Managing Director of Aphelion Capital LLC, Principal at Piper Jaffray Ventures, and a Partner at TVM Techno Venture Management. Dr. Altman continues to work as an emergency physician at Stanford University Medical Center and Kaiser Permanente Medical Center.
"Valeritas' V-GoŽ Disposable Insulin Delivery device is already filling a clear and unmet need in the diabetes market and influencing insulin treatment very positively. The fact that V-Go has repeatedly proven in real-world clinical data to help reduce A1C, with less insulin and at lower cost is quite impressive. Valeritas is truly on the right path. I look forward to contributing to the company's continued success," said Dr. Altman.
Dr. Altman is board certified in emergency medicine and is a fellow of the American College of Emergency Physicians. He earned his medical degree from McGill University and holds an MBA from the University of Chicago, Booth School of Business.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' flagship product, the V-GoŽ Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate infusion of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery system on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit http://www.valeritas.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.